We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Drugmakers Unlikely to Pursue Generic Xifaxan Anytime Soon
Drugmakers Unlikely to Pursue Generic Xifaxan Anytime Soon
December 6, 2011
The FDA’s rigorous new bioequivalence roadmap for Salix Pharmaceuticals’ diarrhea drug Xifaxan and the antibiotic’s long-term patents likely mean scant drugmaker interest in pursuing a generic anytime soon, according to a Wall Street analyst.